Intraoperative Imaging for the OR of Today

Intraoperative imaging using MRI brings real-time imaging into the neurosurgical suite, complementing other methods of helping neurosurgeons visualize their operating fields. Neurosurgical interest seems high, but with the technology new and extremely expensive, adoption rates are at a crawl. Two big players, Siemens and GE, are in the market. Now, Odin Medical, an Israeli start-up, is offering a lower cost, but less powerful system that it says is more practical and adequate for neurosurgeon's needs. A new deal with Medtronic's Surgical Navigation Technologies division should help drive sales.

Over the past decade or so, image-guided surgery has evolved to permit surgeons to navigate areas that are visually restricted in the cranium, spine, and sinus passages. These tools, based on diagnostic images taken before the operation, give surgeons roadmaps with landmarks upon which to follow trackable surgical instruments during surgery. However, in the case of tissue resections, organs and structures often shift, so that the surgeon can no longer be sure of their instrument's precise location in the body.

In recent years, imaged-guided surgery companies have begun to incorporate real-time imaging modalities, for example, C-arm fluoroscopy or ultrasound, in systems to give surgeons more accurate views of the surgical field. Soft tissue like tumors, however, can only be imaged with magnetic resonance imaging (MRI) systems, and economics and logistics have, to date, prevented surgeons from having intraoperative access to MRI

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.